Improvement of skin barrier dysfunction by inhibiting IL4/IL-13 confirms the interwoven impact in AD pathogenesis of the immunological component and the expression of barrier proteins as well as ceramides and tight junction quality. Here, IL13 is linked to Alzheimer disease.